Equillium (NASDAQ: EQ) — Perfil da empresa, notícias e dados financeiros
Equillium focuses on developing therapies for severe autoimmune diseases, aiming to transform patient lives through innovative treatments.
Equillium
Equillium (NASDAQ:EQ) is a biotechnology firm focused on developing therapies for severe autoimmune and inflammatory disorders. Their approach hinges on leveraging deep understanding of immunology to create innovative treatments. The company's pipeline includes projects targeting conditions such as graft-versus-host disease, uncontrolled asthma, and lupus nephritis, highlighting a commitment to addressing significant unmet medical needs. With a mission geared towards transforming the lives of patients by advancing first-in-class therapies, Equillium's strategies revolve around rigorous research, clinical development, and strategic collaborations to expedite the delivery of their therapeutic solutions to the market.
Resumo
Operações
Produtos e/ou serviços de Equillium
- Itolizumab, a monoclonal antibody aimed at treating autoimmune and inflammatory diseases.
- A clinical trial focusing on the management and treatment of acute graft-versus-host disease.
- Studies on the efficacy of itolizumab in treating lupus nephritis, an autoimmune condition affecting the kidneys.
- Research into the application of itolizumab for asthma, exploring new treatments for severe respiratory conditions.
- Development of therapies targeting uncontrolled asthma, aiming to improve quality of life for patients.
- Investigations into the potential of itolizumab in treating COVID-19 related complications, addressing the global pandemic.
equipe executiva do Equillium
- Bruce SteelCo-Founder, CEO & Director
- Stephen ConnellyChief Scientific Officer & President
- Christine ZedelmayerSenior VP & COO
- Penny TomSenior VP of Finance & Principal Accounting Officer
- Michael MooreVice President of Investor Relations & Corporate Communications
- Snehal NaikChief Development Officer
- Lisette AcevedoVice President of Clinical Development
Principais indicadores financeiros
Resultados divulgados pela Equillium, em USD.
- Cap. de mercado
- 111,3 mi
- Receita (TTM)
- 4,4 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.1
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 130 mil | -23,6 mi | -22,4 mi | |
| 41,1 mi | -8,3 mi | -8,1 mi | |
| 36,1 mi | -14,5 mi | -13,3 mi | |
| 15,8 mi | -62,1 mi | -62,4 mi |